Tuberculosis (TB) remains a pressing global health challenge, necessitating precise and reliable biomarkers for early detection. Lipoarabinomannan (LAM), an FDA-approved biomarker (Monoclonal Antibody-MBS320597), holds significant potential due to its association with the